[A25-93] Vutrisiran (transthyretin amyloidosis with cardiomyopathy) – Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2025
Project no.:
A25-93
Commission:
Commission awarded on 07.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-93
| Project no. | Title | Status |
|---|---|---|
| A22-114 | Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V | Commission completed |